Topics

High Lipoprotein and Cardiovascular Disease Risk

Elevated lipoprotein-related cardiovascular risk is driven primarily by atherogenic particles rather than by total cholesterol alone. Low-density lipoprotein, triglyceride-rich remnants, and lipoprotein (a) transport cholesterol or related lipid cargo into pathways that promote atherosclerosis, inflammation, and dysfunction of leukocytes, vascular cells, and cardiac cells. Apolipoprotein B provides a count-related measure of circulating atherogenic particles and can reveal risk that is underestimated by LDL cholesterol when the two measurements are discordant. Evidence synthesized across diverse cohorts indicates that apoB predicts atherosclerotic cardiovascular disease more accurately than LDL cholesterol and often more accurately than non-HDL cholesterol Accordingly, the word high must be tied to a specific particle concentration, particle number, or cholesterol cargo before risk can be interpreted[1][2].

Residual lipid risk remains after intensive LDL lowering because different particles act through partly distinct mechanisms. LDL and remnant particles contribute to arterial cholesterol deposition and plaque development; triglyceride-rich remnants may also intensify intimal inflammation. Lipoprotein (a) contains an apoB-like particle linked to apolipoprotein (a), promotes inflammation and atherogenesis, and has proposed antifibrinolytic and prothrombotic properties related to apolipoprotein (a) homology with plasminogen. ApoB and non-HDL cholesterol integrate several particle classes, whereas direct Lp (a) measurement identifies a genetically dominated risk component that routine LDL testing cannot resolve. Measurement choice therefore changes both risk interpretation and the residual pathway selected for treatment This distinction explains why apparently controlled LDL cholesterol can coexist with substantial apoB, remnant, or genetically determined Lp (a) burden[1][3][4].

Clinical application requires a structured lipid profile. LDL cholesterol remains the principal treatment target, but apoB can refine risk before and during therapy, characterize lipoprotein phenotypes, and support family cascade screening. Lp (a) testing is practical with a nonfasting blood draw and is especially important because roughly one fifth of the population has genetically elevated concentrations and standard oral dyslipidemia therapy lowers it poorly. RNA-based agents directed at Lp (a), including antisense and small-interfering RNA approaches, produce substantial concentration reductions, while outcome trials are evaluating whether this translates into fewer cardiovascular events. Risk management should still address LDL and all modifiable factors Family testing becomes especially useful when an inherited phenotype is identified because relatives may carry risk before clinical disease appears[2][4][5][6].

Important gaps include terminology, assay standardization, thresholds, and outcome evidence. A high HDL cholesterol concentration is not interchangeable with a high burden of apoB particles or Lp (a), and ratios can obscure particle-specific biology. Future care should test whether apoB-guided treatment improves outcomes beyond LDL-guided care and determine how Lp (a) thresholds should account for ancestry, sex, renal function, inflammation, and assay method. Trials of RNA therapeutics must establish cardiovascular benefit and long-term safety rather than relying on biomarker lowering alone. Integrated models should assign residual risk to LDL, remnants, Lp (a), or another pathway so that additional therapy is personalized instead of applied uniformly A treatment algorithm should also verify adherence and secondary dyslipidemia before assigning persistent events to an untreated residual-lipid pathway. Particle number, cholesterol content, genetic burden, and inflammatory context should be measured separately when they point to different therapeutic options[1][5][6][7].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L009 Kinase Inhibitor Library
Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. Kinase inhibitor library designed by MCE contains 3,998 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.
125
HY-L022M FDA-Approved Drug Library Mini
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,236 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.
101
HY-L068 Flavonoids Library
Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc. MCE offers a unique collection of 583 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.
98
HY-L026 Clinical Compound Library
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2,568 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.
90
HY-L091 Lipid Metabolism Compound Library
Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation. MCE offers a unique collection of 1,026 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.
85
HY-L043 Lipid Compound Library
Lipids are a diverse and ubiquitous group of compounds which have many key biological functions, such as acting as structural components of cell membranes, serving as energy storage sources and participating in signaling pathways. Several studies suggest that bioactive lipids have effects on the treatment of some mental illnesses and metabolic syndrome. For example, DHA and EPA are important for monoaminergic neurotransmission, brain development and synaptic functioning, and are also correlated with a reduced risk of cancer and cardiovascular disease in clinical and animal studies. MCE supplies a unique collection of 2,028 lipid and lipid derivative related compounds including triglycerides, phospholipids, sphingolipids, steroids and their structural analogues or derivatives. MCE lipid compound library can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).
84
HY-L146 Metabolic Enzyme Compound Library
Metabolism is the set of life-sustaining chemical reactions in organisms that maintain cell homeostasis. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of molecules including glucose metabolism, lipid metabolism and amino acid or protein metabolism within a cell or tissue. As catalysts, enzymes are crucial to metabolism as they allow a reaction to proceed more rapidly and tregulate the rate of a metabolic reaction. Due to the importance of metabolic balance in the organism, the abnormal function of metabolic enzymes often leads to the occurrence of a variety of metabolic diseases, such as diabetes, obesity, cardiovascular disease, etc. MCE designs a unique collection of 4,407 metabolic enzymes related small molecules, which is an important tool for studying the metabolic activities of organisms and developing drugs for metabolic diseases.
84
HY-L009M Kinase Inhibitor Library Mini
Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available. The MCE Kinase Inhibitor Library Mini contains 270 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.
83
HY-L119 Potassium Channel Compound Library
Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. There are four major classes of K channels: voltage-gated potassium channel, calcium-activated potassium channel, inwardly rectifying potassium channel and tandem pore domain potassium channel. There is growing evidence that dysfunction in potassium channels correlates with several diseases, such as chronic hypertension, diabetes, hypercholesterolemia and atherosclerosis, etc. MCE Potassium Channel Compound Library consists of 337 potassium channel inhibitor and activators, which is a useful tool to discover drugs for cardiovascular diseases and potassium channel research.
83
HY-L141 Off-patent Drug Library
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk. MCE carefully prepared a unique collection of 2,921 off-patent drugs, which is a good choice for drug repurposing.
83
HY-L208 Bile Acids Library
Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases. MCE included 62 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.
83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.
83
HY-L251 Ionizable Lipid Compound Library
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application. To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.
83
HY-L265 Cholesterol Metabolism Compound Library
Cholesterol is a crucial lipid that maintains cell membrane structure, serves as a precursor for the synthesis of steroid hormones and bile acids, and plays an important role in cell signal transduction and membrane function regulation. Intracellular cholesterol levels are precisely controlled by multiple processes, including synthesis, uptake, transport, esterification, storage, and efflux. Dysregulation of cholesterol metabolism is closely associated with diseases such as atherosclerosis, fatty liver disease, metabolic syndrome, and various cancers. The Cholesterol Metabolism Compound Library contains 558 compounds and focuses on cholesterol metabolism and homeostatic regulation. It provides an efficient tool for mechanistic studies of cholesterol metabolism and for drug discovery in metabolism‑related diseases.
83
HY-N0177 Diosgenin
Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway. Diosgenin is an exogenous activator of Pdia3/ERp57. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.
11
HY-132591 Inclisiran
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
9
HY-132591A Inclisiran sodium
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
9
HY-14668 Lomitapide mesylate
Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8+ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia.
7
HY-120088A PF-06446846 hydrochloride
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.
7
HY-12402 SBC-115076
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.
5
HY-P2136 COG1410
COG1410 is an apolipoprotein E-derived peptide and an apoptosis inhibitor. COG1410 exerts neuroprotective and antiinflammatory effects in a murine model of traumatic brain injury (TBI). COG1410 can be used for the research of neurological disease.
5
HY-W009722 Sodium diethylcarbamodithioate trihydrate
Sodium diethylcarbamodithioate (Ditiocarb sodium) trihydrate is a copper reagent. The reaction with Cu2+ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethylcarbamodithioate trihydrate can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer.
4
HY-A0143 Dihomo-γ-linolenic acid
Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system.
4
HY-108764 Mipomersen sodium
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH).
4
HY-NP013 Oxidized low density lipoprotein (mouse)
Oxidized low density lipoprotein (mouse) (Mouse ox-LDL) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration. Oxidized low density lipoprotein (mouse) can be used to construct an in vitro model of AS.
4
HY-W127355 Kdo2-Lipid A
Kdo2-Lipid A is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
3
HY-N8277 Kdo2-Lipid A ammonium
Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxin activity equal to LPS. Kdo2-Lipid A ammonium is highly selective for TLR4. Kdo2-Lipid A ammonium stimulates the release of both TNF and PGE2.

Source: E. coli

3
HY-P99459 Baminercept
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome.
3
HY-122208 SGA360
SGA360 suppress inflammatory SAA1 signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response element (partial antagonist).
3
HY-P2341 Angiopep-2 hydrochloride
Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer.
LDLR  
3
HY-P75215 FABP4 Protein, Mouse (His)
The FABP4 protein binds hormone receptors, fatty acids, and transports them. It regulates thermogenesis, brown fat cell differentiation, and response to lithium ion. It is located in the cytoplasm and nucleus, and is expressed in adipose tissue, CNS, genitourinary system, gut, and heart. It shares orthology with human FABP4. Biased expression is seen in subcutaneous and genital fat pads. FABP4 Protein, Mouse (His) is the recombinant mouse-derived FABP4 protein, expressed by E. coli , with N-His labeled tag.

Species: Mouse; Source: E. coli

3
HY-P99646 Golocdacimab
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.

Species: Human

2
HY-P6306 CS-6253
CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
2
HY-113328 Aminoadipic acid
Aminoadipic acid is an orally active lysine oxide derivative. Aminoadipic acid induces ROS generation, increases free Ca2+, decreases SOD, and activates TXNIP/NLRP3 pathway. Aminoadipic acid has pro-inflammatory effects. Aminoadipic acid can be used in atherosclerosis research.
2
HY-P1050A COG 133 TFA
COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM.
2
HY-125864 Fibrinogen (Bovine)
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases.
2
HY-B1699 Metrizoic acid
Metrizoic acid (Metrizoate) is an ionic contrast medium. Metrizoic acid (Metrizoate) shows high osmolality and has a risk of inducing allergic reactions.
1
HY-N0857 Deoxyandrographolide
Deoxyandrographolide is an orally active lactone found in the Andrographis paniculata Nees. Deoxyandrographolide shows a KD of 38.4 μM of HDAC1. Deoxyandrographolide enhances GLUT4 plasma membrane translocation, activates PI3K and AMPK-dependent signaling pathways, suppresses fasting blood glucose, serum insulin, triglycerides, and LDL-cholesterol levels. Deoxyandrographolide enhances HDAC1 expression via inhibited ubiquitination degradation, represses H3K4me3, improves chromosome stability, and restrains aging biomarkers p16, p21, γH2A.X, p53 and ROS production. Deoxyandrographolide interacts with Foot-and-Mouth Disease Virus 3Cpro active site, inhibits protease and IFN-antagonist activity, derepresses ISG expression, and inhibits viral replication. Deoxyandrographolide can be used for the researches of type 2 diabetes mellitus, vascular senescence and virus infection.
1
HY-W782032 3D-Monophosphoryl Lipid A-5
3D-Monophosphoryl Lipid A-5 (3D-MPLA-5) is a TLR agonist that serves as a vaccine adjuvant and enhances the immunogenicity of vaccines.
1
HY-N6071 Secoisolariciresinol
Secoisolariciresinol ((-)-Secoisolariciresinol) is a plant lignan and a precursor of enterolignans. Secoisolariciresinol can be converted into enterodiol and enterolactone by intestinal microflora. Secoisolariciresinol may reduce the risk of cancer and cardiovascular diseases.
1
HY-N2339 Cholesteryl behenate
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.
1
HY-P9929 Bezlotoxumab
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention.

Species: Human

1
HY-145001 20-HC-Me-Pyrrolidine
20-HC-Me-Pyrrolidine (compound AI-3d) is a potent Aster protein inhibitor with IC50s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER).
1
HY-N2419 Erythrodiol
Erythrodiol is an olive oil component. Erythrodiol promotes Cholesterol efflux (ChE) by selectively inhibiting the degradation of ABCA1 protein. Erythrodiol is a good candidate to be further explored for therapeutic or preventive application in the context of atherosclerosis.
1
HY-W074890 Palmitoylglycine
Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA.
1
HY-117832 Pyripyropene A
Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.

Source: filamentous fungi

1
HY-W040055 Neopterin
Neopterin is an immune system activator metabolized by GTP and can be produced by activated macrophages. Neopterin has the potential to resist vascular inflammation and atherosclerosis. Neopterin inhibits the phosphorylation of NF-κB and promotes the expression of PPAR-γ, thereby suppressing the inflammatory response of vascular endothelial cells, reducing the formation of macrophage foam cells, and regulating the migration and proliferation of vascular smooth muscle cells. Neopterin can be used in research fields such as cardiovascular diseases (such as atherosclerosis), inflammation-related diseases and tumor immunomonitoring.
1
HY-103076 EZ-482
EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with Kds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas.
1
HY-P9928A Alirocumab (anti-PCSK9)
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.

Species: Human

1
HY-113301 Hexacosanoic acid
Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
1
HY-W251428 Phosphatidylglycerols (egg) sodium salt
Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV).
1
HY-P9928 Alirocumab
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.

Species: Human

1
HY-148673 Laroprovstat
Laroprovstat (AZD0780) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of <200 nM. Laroprovstat binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. Laroprovstat inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. Laroprovstat can be used for the research of hypercholesterolemia.
1
HY-134124 Glutathione ethyl ester
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense.
1
HY-P99187 Bococizumab
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.

Species: Human

1
HY-P7533 Apolipoprotein H/APOH Protein, Human (HEK293, His)
Apolipoprotein H Protein, Human (HEK293, His) expresses in HEK293 with a His tag at the C-terminus. Apolipoprotein H (ApoH) is the main target of anti-phospholipid antibodies (aPLs) found in many patients with systemic lupus erythematosus and antiphospholipid syndrome (APS).

Species: Human; Source: HEK293

1
HY-K0533A 2× High-Fidelity PCR Master Mix (with Dye)

MCE 2× High-Fidelity PCR Master Mix (with Dye) is a new type of ready-to-use high-fidelity PCR amplification master mix.During the reaction, only template and primers need to be added to quickly and efficiently complete the PCR process, reducing the risk of contamination during operation. The 1 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

1
HY-K1103 Coomassie Blue Fast Staining Solution (No Heating, 10×)

MCE Coomassie Blue Fast Staining Solution (No Heating, 10×) uses Coomassie Brilliant Blue G250 as the dye. It can be used for rapid, sensitive staining of protein gels in SDS-PAGE or Native-PAGE without contamination, or for detecting residual proteins on PAGE gels after Western Blot transfer. The 25 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

1
HY-K2016 Protein Transfection Reagent

MCE Protein Transfection Reagent is a cationic lipid mixture for complexation with proteins, peptides, antibodies and other biologically active molecules to allow their direct intracellular delivery.

1
HY-W1126955 Enlicitide decanoate
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease.
/
HY-B0251S1 Eplerenone-13C,d3
Eplerenone-13C,d3 (Epoxymexrenone-13C,d3) is 13C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).
/
HY-B2015S Carbosulfan-d18
Carbosulfan-d18 is the deuterium labeled Carbosulfan. Carbosulfan is an orally active AChE inhibitor that hydrolyzes to Carbofuran in organisms to exert insecticidal effects. Carbosulfan exhibits broad-spectrum insecticidal activity, and it also induces severe oxidative stress by enhancing lipid peroxidation and impairing the antioxidant defense system. Carbosulfan causes reproductive toxicity in male rats and developmental disorders in their offspring. Carbosulfan shows persistence in paddy field environments and potential hazards to non-target organisms, and it is commonly used in studies related to reproductive toxicity and environmental risk assessment.
/
HY-N20275 Cashew extract
Cashew extract (Cashew kernel extract) is an extract from cashew nuts (Anacardium occidentale) that can lower LDL cholesterol.
/
HY-P10906 Talovirtide
Talovirtide is a peptide containing L-valyl.
/
HY-N15786 DSPE-RGD Lipid sodium
DSPE-RGD Lipid sodium is a lipid containing DSPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
/
HY-B0347S3 Lacidipine-13C4
Lacidipine-13C4 is 13C labeled Lacidipine (HY-B0347). Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI).
/
HY-B0144AS3 Pitavastatin-d4-1 sodium
Pitavastatin-d4-1 (NK-104-d4-1) sodium is the deuterium labeled Pitavastatin sodium (HY-B0144B). Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.
/
HY-P1142S GLP-2(rat) (Ala-13C3,15N)
GLP-2(rat) (Ala-13C3,15N) is 13C and 15N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
/
HY-P10258 KRES peptide
KRES peptide is an apolipoprotein with 4 amino acid residues. KRES peptide interacts with lipids, reduces lipoprotein lipid hydroperoxides (LOOH), activates antioxidant enzymes associated with high-density lipoprotein. KRES peptide exhibits anti-inflammatory and anti-atherogenic properties. KRES peptide is orally active.
/
HY-P1824 C-Reactive Protein (CRP) (201-206)
C-Reactive Protein (CRP) 201-206 is the 201-206 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
/
HY-P1836 C-Reactive Protein (CRP) (77-82)
C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of C-Reactive Protein. C-Reactive Protein (CRP), the prototypic marker of inflammation, is a cardiovascular risk marker and may promote atherogenesis.
/
HY-P991510 CDX-1140
CDX-1140 is a fully human IgG monoclonal antibody and CD40 agonist, with a Kd value of 0.01 nM against human targets. The epitope of CDX-1140 locates at CD40 CRD1 and avoids the CD40L binding site. It activates DCs and B cells, drives NF-κB reporter gene activation, exhibits agonist activity independent of FcR cross-linking, and shows a synergistic effect with recombinant CD40L. CDX-1140 does not induce systemic cytokine release, exerts direct and immune-mediated anti-tumor activity in tumor xenografts, and has favorable safety profiles. When used as a local vaccine adjuvant in combination with 6MHP+mBRAF+poly-ICLC, CDX-1140 increases the number of DC-LAMP+ DCs and induces Th1 CD4+ responses in high-risk melanoma. CDX-1140 can be used in studies related to B-cell lymphoma, bladder cancer and high-risk melanoma.

Species: Human

/
HY-N20390 Scrophularia ningpoensis extract
Scrophularia ningpoensis extract is an orally effective hypoglycemic and antioxidant agent. Scrophularia ningpoensis extract reduces fasting blood glucose levels, increases plasma insulin levels, ameliorates impaired antioxidant status, scavenges free radicals, inhibits lipid peroxidation, and decreases elevated serum creatinine and serum urea levels. Scrophularia ningpoensis extract reduces the risk of developing diabetic complications. Scrophularia ningpoensis extract is applicable to diabetes-related research.
/
HY-159672 3D-Monophosphoryl Lipid (12,16)
3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
/
HY-P1184 HNGF6A
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo.
/
HY-P10577 RAG8 peptide
RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research.
/
HY-D3499 (E,E)-3,5-Bis(phenylethenyl)-BODIPY lipid stain
(E,E)-3,5-Bis(phenylethenyl)-BODIPY lipid stain is a fluorescent dye for intracellular lipid droplets. It is primarily used for specific fluorescent labeling and dynamic tracking of lipid droplets in living or fixed cells (Ex/Em = 627 nm/640 nm).
/
HY-P11495 myr-RGT
myr-RGT is a nutmeg acylated RGT peptide. myr-RGT can be used to inhibit extracellular signaling of integrin β3. myr-RGT can be used in the research of atherosclerosis and other related conditions.
Integrin  
/
HY-N16329 Lipid A (14:0(5)-iso15:0(1)) diammonium
Lipid A (14:0(5)-iso15:0(1)) diammonium, a lipid, is an adjuvant. Lipid A (14:0(5)-iso15:0(1)) diammonium has immunostimulatory properties.
/
HY-P2251 T-peptide
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.
/
HY-B0388S1 Probucol-d6
Probucol-d6 is deuterium labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
/
HY-P5169 LVGRQLEEFL (mouse)
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
/
HY-N16301 Lipid A (14:0(5)-cyclopropyl17:0(1)) diammonium
Lipid A (14:0(5)-cyclopropyl17:0(1)) diammonium, a lipid, is an adjuvant. Lipid A (14:0(5)-cyclopropyl17:0(1)) diammonium has immunostimulatory properties.
/
HY-P2424 Cholecystokinin-J
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca2+ release.
/
HY-P11455 Lipopeptide CPE4
Lipopeptide CPE4 is a PEG-modified peptide E4 [(EIAALEK)4]. Lipopeptide CPE4 is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPE4 triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPE4 can be used for drug delivery research.
Liposome  
/
HY-113221AS Isovalerylcarnitine-d3 chloride
Isovalerylcarnitine-d3 chloride is the deuterium labeled Isovalerylcarnitine chloride (HY-145542). Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
/
HY-P10872 P315V3
P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC50s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC50 of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models.
SARS-CoV  
/
HY-B0388S Probucol-13C3
Probucol-13C3 is the 13C-labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
/
HY-D1409 DMTr-4'-F-U-CED-TBDMS phosphoramidite
DMTr-4'-F-U-CED-TBDMS phosphoramidite (DMTr-4'-F-uridine-CED-TBDMS phosphoramidite), a dye reagent for oligonucleotide labeling, can be used for the research of applications in RNA therapeutics, RNA aptamers, and ribozymes for elucidating RNA structure. DMTr-4'-F-U-CED-TBDMS phosphoramidite represents a probe with wide utility for elucidation of RNA structure.
/
HY-D3197 CDg16
CDg16 is a selective fluorescent dye targeting SLC18B1 (λabs/λem=458/544 nm) that is actively transported into lysosomal vesicles of activated macrophages independent of the endocytic pathway. CDg16 enables highly specific vesicle localization in live cells. CDg16 exhibits no cytotoxicity and accurately distinguishes activated M1 and M2 subsets from different origins. CDg16 shows low background staining in non-activated cells and normal organs, making it suitable for time-lapse imaging. In preclinical animal models of inflammatory sites, atherosclerotic plaques and liver inflammation, CDg16 allows visualization of activated macrophages. CDg16 can be used to study inflammation-related diseases and atherosclerosis.
/
HY-P992380 IBC-Ab002
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease.

Species: Human

/
HY-114977S Avenanthramide A-d4
Avenanthramide A-d4 is the deuterium labeled Avenanthramide A (HY-114977). Avenanthramide A is an orally active phytoalexin that targets the RNA helicase DDX3 with a KD of 8.8 μM. Avenanthramide A induces mitochondrial swelling and increased ROS production, and triggers apoptosis in CRC cells. Avenanthramide A inhibits smooth muscle cell proliferation and enhances nitric oxide production. Avenanthramide A can be used in research on colorectal cancer and atherosclerosis.
/
HY-P2682 MMP-8/MMP-26 Fluorogenic substrate
MMP-8/MMP-26 Fluorogenic substrate (DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg) is a matrix metalloproteinase-8 (MMP-8) fluorogenic substrate. MMP-8/MMP-26 Fluorogenic substrate can be used for the research of atherosclerosis, pulmonary fibrosis, and sepsis.
/
HY-D3170 C-HBrO-GGT
C-HBrO-GGT is a dual-target fluorescent indicator with specificity for γ-glutamyl transpeptidase (GGT) and hypobromous acid (HBrO). C-HBrO-GGT acts as a substrate for GGT and HBrO, undergoing enzymatic or chemical modification to trigger channel-specific fluorescence, with sequential activation requiring initial GGT hydrolysis. C-HBrO-GGT enables simultaneous in vitro and in vivo fluorescence detection of GGT and HBrO. C-HBrO-GGT identifies mature atherosclerotic plaque positions and provides early warning of plaque formation before visual or classical immunofluorescent detection. C-HBrO-GGT can be used for the research of atherosclerosis (Ex/Em = 370 nm/500 nm).
/
HY-P4134 Lipid Membrane Translocating Peptide
Lipid Membrane Translocating Peptide is a cell-penetrating peptide consisting of 13 amino acids.
Others  
/
HY-P11836 IL-1β-IN-3
IL-1β-IN-3 is a IL-1β inhibitor with an IC50 value of 0.021 nM. IL-1β-IN-3 can be used in the research of atherosclerosis and inflammatory diseases.
/
HY-P1142A GLP-2(rat) TFA
GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
Apoptosis  
/
HY-P992470 STT-5058
STT-5058 (ARGX-116; NN5058) is a human monoclonal antibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases.

Species: Human

/
HY-P1166 UFP-803
UFP-803 is a potent urotensin-II receptor (UT) ligand. UFP-803 has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
/
HY-107965 Safflower oil (from Carthamus tinctorius seed)
Safflower oil (from Carthamus tinctorius seed) is rich in unsaturated fatty acids such as linoleic acid and oleic acid, as well as tocopherols and phenolic compounds, and exhibits antioxidant, anti-aging and blood lipid-regulating effects. Safflower oil (from Carthamus tinctorius seed) inhibits the activities of collagenase and elastase, and exerts antioxidant activity by scavenging free radicals. Linoleic acid in safflower oil (from Carthamus tinctorius seed) reduces blood cholesterol levels. Safflower oil (from Carthamus tinctorius seed) can be applied to research in fields such as skin aging, atherosclerosis, edible oil processing and industrial raw material development.
/
HY-P99696 Lerodalcibep
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases.
/
HY-N15803 DOPE-RGD Lipid sodium
DOPE-RGD Lipid sodium is a lipid containing DOPE and RGD peptides that can be used to prepare lipid nanoparticles for drug delivery.
/
HY-131306B 2-Hexadecenoic acid
2-Hexadecenoic acid is a natural unsaturated fatty acid. It is ubiquitously present in various animal and plant tissues, especially adipose tissue and certain vegetable oils, such as macadamia nut oil. 2-Hexadecenoic acid has unique chemical properties that make it an important component of cell membranes and storage lipids, and participates in various metabolic processes such as lipid metabolism and inflammation. It's also been linked to potential health benefits, including improved insulin sensitivity and a lower risk of heart disease.
/
HY-P1166A UFP-803 TFA
UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
/
HY-P11071 PCSK9 Inhibitor, EGF-A
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor with LDLR degradation inhibitory activity and LDLR recycling promoting activity. PCSK9 Inhibitor, EGF-A is a synthetic peptide consisting of 42 amino acid residues, which contains the calcium-binding site of the epidermal growth factor A domain (EGF-A). PCSK9 Inhibitor, EGF-A reduces plasma LDL cholesterol levels by maintaining hepatic LDLR levels and enhancing the clearance capacity of circulating LDL. PCSK9 Inhibitor, EGF-A can be used in research related to hypercholesterolemia, premature atherosclerosis, coronary heart disease and familial hypercholesterolemia.
/
HY-P11351 Precursor-HhH
Precursor-HhH is a nucleic acid-binding peptide capable of non-specific interactions with RNA and double-stranded DNA (dsDNA). Precursor-HhH is promising for research of nucleic acid-targeted therapeutics.
/
HY-P1949 Cyclic MKEY
Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice.
/
HY-D1408 DMTr-4'-Me-U-CED-TBDMS phosphoramidite
DMTr-4'-Me-U-CED-TBDMS phosphoramidite (DMTr-4'-Methyluridine-CED-TBDMS phosphoramidite), a dye reagent for oligonucleotide labeling, can be used for the research of applications in RNA therapeutics, RNA aptamers, and ribozymes for elucidating RNA structure. DMTr-4'-Me-U-CED-TBDMS phosphoramidite represents a probe with wide utility for elucidation of RNA structure.
/
HY-N7729 Sekikaic acid
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration.

Source: Ramalina species

/
HY-B0144S Pitavastatin-d4 hemicalcium
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
/
HY-113301S Hexacosanoic acid-d4
Hexacosanoic acid-d4 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
/
HY-P991574 MEDI-5884
MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC50 of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its Kd values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.

Species: Human

/
HY-121855 1-Monoelaidin
Monoeladin is an ester derivative of glycerin and oleic acid, which are commonly found in various vegetable and animal fats. Monoeladin has unique chemical properties that make it an important intermediate in the biosynthesis of other lipid molecules, especially in the formation of triglycerides and phospholipids. It also plays a role in food science as a partial replacement for saturated fat, which has been linked to an increased risk of heart disease.
/
HY-P1184A HNGF6A TFA
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
/
HY-W002112S1 (±)-Nornicotine-d7
(±)-Nornicotine-d7 is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia.
/
HY-145542S Isovalerylcarnitine-d9 chloride
Isovalerylcarnitine-d9 chloride is the deuterium labeled Isovalerylcarnitine chloride (HY-145542). Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
/
HY-B0347S1 Lacidipine-13C8
Lacidipine-13C8 is the deuterium labeled Lacidipine. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI).
/
HY-P992023 APX002
APX002 is an anti-IL-1β humanized monoclonal antibody that binds to IL-1β with an affinity of 1.99×10?10M. APX002 blocks IL-1β receptor binding, inhibits IL-1β-induced downstream cell signaling and biological effects.APX002 can be used for the research of rheumatoid arthritis, diabetes, gout, cryopyrin-associated periodic syndrome, chronic obstructive pulmonary disorder, atherosclerosis, vasculitis.

Species: Human

/
HY-W724404 N-Oleoyl serinol-d5
N-Oleoyl serinol-d5 (Oleoyl serinol-d5) is the deuterium labeled N-Oleoyl serinol (HY-122788). N-Oleoyl serinol is a ceramide analog that can be used in stem cell therapy to prevent stem cells from developing into teratomas. N-Oleoyl serinol induces apoptosis in residual pluripotent embryoid body-derived cells (EBCs), prevents teratoma formation, and enriches EBC cells that undergo neural differentiation after transplantation.
/
HY-P1142S1 GLP-2(rat) (Ala-13C3,15N) TFA
GLP-2(rat) (Ala-13C3,15N) TFA is 13C and 15N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
/
HY-B1834S1 Megestrol-d5
Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause glucocorticoid-like effects and an increased risk of mental disorders.
/
HY-P991947 ELB041
ELB041 (AFS98) is a rat monoclonal anti-murine c-fms antibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis.

Species: Human

/
HY-P10188 apoB (4372-4392)
apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC50 of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.
/
HY-W012974S 3-Amino-2-methylpropanoic acid-d3
3-Amino-2-methylpropanoic acid-d3 is the deuterium labeled 3-Amino-2-methylpropanoic acid. 3-Amino-2-methylpropanoic acid could induce browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors.
/
HY-159671 3D-Monophosphoryl Lipid (14)
3D-Monophosphoryl Lipid (14) (3D-Monophosphoryl Lipid (14)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
/
HY-D0584 Reactive orange 86
Reactive orange 86 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-D0668 Reactive orange 13
Reactive orange 13 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-126363S Ditiocarb-d10
Ditiocarb-d10 (Diethyldithiocarbamic acid-d10) is the deuterium labeled Ditiocarb (HY-126363). Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast cancer.
/
HY-D0653 Reactive orange 35
Reactive orange 35 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-15790S Elobixibat-d5
Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
/
HY-P990822 Anti-Mouse TIM-1/CD365 Antibody (3D10)
Anti-Mouse TIM-1/CD365 Antibody (3D10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse TIM-1/CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can block mouse T cell immunoglobulin and mucin domain 1 (TIM-1) also known as CD365. Anti-Mouse TIM-1/CD365 Antibody (3D10) can be used for the researches of inflammation, immunology and cardiovascular disease, such as graft-versus-host disease (GVHD), airway inflammation and atherosclerosis.

Species: Mouse

/
HY-D0622 Reactive Green 19
Reactive Green 19 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-D0514 Reactive blue 5
Reactive blue 5 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-D0522 Reactive orange 16
Reactive orange 16 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-D0639 Reactive Brown 23
Reactive Brown 23 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-D0669 Reactive orange 4
Reactive orange 4 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-D0661 Reactive red 45
Reactive red 45 is common textile dyes that can be adsorbed onto single-walled carbon nanotubes (SWCNTs) through electrostatic interactions, allowing the separation of residual dyes.
/
HY-W440811 6-Bromohexyl 2-hexyldecanoate
6-Bromohexyl 2-hexyldecanoate is a lipid. 6-Bromohexyl 2-hexyldecanoate can be used to build lipid nanoparticles and nanomaterials.
Liposome  
/
HY-W654009 Loxoprofen-d3
Loxoprofen-d3 is deuterium labeled Loxoprofen. Loxoprofen is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen can reduce atherosclerosis and shows antitumor activity.
/
HY-N14990 Pneumocandin C0
Pneumocandin C0 is the isomer of Pneumocandin B0 (HY-17578) with antifungal activity, which is found by carrying out fermentations of Glarea lozoyensis at a high residual fructose concentration.

Source: Glarea lozoyensis

Fungal  
Infection  
/
HY-N0466R Rebaudioside A (Standard)
Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
/
HY-W074890R Palmitoylglycine (Standard)
Palmitoylglycine (Standard) is the analytical standard of Palmitoylglycine. This product is intended for research and analytical applications. Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA[1][2][3].
/
HY-P11501 AAKLVFF
AAKLVFF is an oligopeptide capable of self-assembling into nanotubes. AAKLVFF can be derived from the core section of β-amyloid. AAKLVFF becomes the first methanol compatible LC alignment medium for residual dipolar coupling measurement.
/
HY-A0014S Ramelteon-d5
Ramelteon-d5 is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.
/
HY-P5169A LVGRQLEEFL (mouse) TFA
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
/
HY-P1142 GLP-2(rat)
GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
Apoptosis  
/
HY-P4339 Ala-Phe-Lys-AMC
Ala-Phe-Lys-AMC is a fluorogenic substrate, which can be used for residual plasmin activity assay.
/
HY-W700437 threo-9,10-Dihydroxystearic acid
Threo-9,10-Dihydroxystearic acid is a synthetic dihydroxy fatty acid with the activity of altering lipid bilayer packing and fluidity. Threo-9,10-Dihydroxystearic acid can be used to study the dynamic properties of lipid membranes. Threo-9,10-Dihydroxystearic acid exhibits important biological functions in cell membranes or synthetic lipid models.
/
HY-113301S1 Hexacosanoic acid-d4-1
Hexacosanoic acid-d4-11 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
/
HY-17504BS2 Rosuvastatin-13C,d3 sodium
Rosuvastatin-13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
/
HY-P99773 Ongericimab
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia.

Species: Human

/
HY-P99822 Recaticimab
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research.

Species: Human

/
HY-P991333 GSK-315234
GSK-315234 is a human IgG1 monoclonal antibody (mAb) targeting OSM . GSK-315234 can be used in the study of atherosclerosis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

/
HY-A0143S Dihomo-γ-linolenic acid-d6
Dihomo-γ-linolenic acid-d6 (DGLA-d6) is the deuterium labeled Dihomo-γ-linolenic acid. Dihomo-γ-linolenic acid (all-cis-8,11,14-Eicosatrienoic acid) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system.
/
HY-17504BS1 Rosuvastatin-d6 sodium
Rosuvastatin-d6 sodium is deuterium labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
/
HY-P1949A Cyclic MKEY TFA
Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice.
/
HY-17504AS1 Rosuvastatin-d6
Rosuvastatin-d6 (ZD 4522-d6) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
/
HY-B0144AS1 Pitavastatin-d5 sodium
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
/
HY-W015600S 2-Acetamidophenol-d3
2-Acetamidophenol-d3 (Orthocetamol-d3) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation.
/
HY-P990905 Bexatamig
Bexatamig (SAR-443579) is a trifunctional natural killer cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between natural killer cells and CD123-positive tumor cells. By activating natural killer cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes.

Species: Human

/
HY-W011927R 4,4'-Sulfonyldiphenol (Standard)
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) (Standard) is the analytical standard of 4,4'-Sulfonyldiphenol (HY-W011927). This product is intended for research and analytical applications. 4,4'-Sulfonyldiphenol, a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
/
HY-122917 Danshenol A
Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research.
/
HY-W002112S (±)-Nornicotine-d4
(±)-Nornicotine-d4 is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia.
/
HY-P99793 Orticumab
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.

Species: Human

/
HY-114294A DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate
DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor.
/
HY-P991040 hu14.18 (K322A)
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma.
Others  
Cancer  
/
HY-B1337B Glycerophosphoinositol choline
Glycerophosphoinositol choline is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders.
/
HY-113270 Actinine
Actinine is a metabolic and pro-atherogenic intermediate with oral activity. Actinine acts as a substrate for the yeaW/X microbial enzyme complex to generate trimethylamine (TMA). Actinine accelerates atherosclerosis development in a gut microbe-dependent manner. Actinine can be used for the research of atherosclerosis.

Source: Porphyra yezoensis

/
HY-18778 Obicetrapib
Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
/
HY-P99794 Osocimab
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.

Species: Human

/
HY-P4073 ANG1005
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system.
/
HY-145746 Sulfo-Cy5 azide
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm).
/
HY-W007347 1,2-Cyclohexanedione
1,2-Cyclohexanedione is an arginine modification reagent. 1,2-Cyclohexanedione interferes with the degradation of low-density lipoprotein by modifying the arginine group in apolipoprotein. 1,2-Cyclohexanedione can be used in the research of familial hypercholesterolemia.
/
HY-P99505 Ziltivekimab
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease.

Species: Human

/
HY-145727 Volanesorsen
Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.
/
HY-W011824 2′-O-Methyluridine
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

Source: Archaea, Bacteria, and Eukaryota

/
HY-P990202 Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4)
Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) is a mouse-derived IgG1 κ type antibody, targeting to mouse/rat/human LRP1/CD91. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) binds to the β chain of LRP1. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) can be used for western blot (WB) and other detections.

Species: Human/Mouse/Rat

/
HY-145727A Volanesorsen sodium
Volanesorsen (ISIS 304801) sodium is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen sodium is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.
/
HY-143219 SS-Inclisiran sodium
SS-Inclisiran sodium is a sense strand of Inclisiran (HY-132591).
/
HY-N0466 Rebaudioside A
Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.
/
HY-P99125 Anti-Mouse CD16/CD32 Antibody (2.4G2)
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.

Species: Mouse

/
HY-P99209 Motavizumab
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.

Species: Human

/
HY-152857 Muvalaplin
Muvalaplin (LY3473329) is an orally active small molecule apolipoprotein a (apolipoprotein a) inhibitor that binds to the KIV8 domain (Kd = 22 nM) and kringle IV domains 7 and 8, blocks the non-covalent interaction between apo (a) and apoB-100, and prevents Lp (a) assembly, thereby lowering circulating Lp (a) levels. Muvalaplin can be used in research on atherosclerotic cardiovascular disease.
/
HY-P5282 ApoA-I mimetic peptide
ApoA-I mimetic peptide is an ApoA-I mimetic peptide. ApoA-I mimetic peptide has good phosphatidylcholine: cholesterol acyltransferase (LCAT) activation activity. ApoA-I mimetic peptide can be used to synthesize peptide/lipid complexes. ApoA-I mimetic peptide can be used in atherosclerosis research. (The sequence is: PVLDLFRELLNELLEALKQKLK).
/
HY-W011927 4,4'-Sulfonyldiphenol
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.
/
HY-P4153 Enlicitide chloride
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.
/
HY-P70293 FABP4 Protein, Human (His)
FABP4 Protein, expressed mainly in adipocytes, crucially mediates lipid and retinoic acid transport. It binds long-chain fatty acids and retinoic acid, facilitating delivery to nuclear receptors. Functioning as a monomer and forming homodimers, FABP4 interacts with PPARG, contributing to its involvement in fatty acid metabolism and signaling pathways. FABP4 Protein, Human (His) is the recombinant human-derived FABP4 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P7534A Apolipoprotein H/APOH Protein, Mouse (HEK293, His)
Apolipoprotein H/APOH protein binds to heparin, phospholipids, and dextran sulfate, preventing activation of the blood coagulation cascade by interacting with phospholipids on damaged cell surfaces. Apolipoprotein H/APOH Protein, Mouse (HEK293, His) is the recombinant mouse-derived Apolipoprotein H/APOH protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

/
HY-P7524 Apolipoprotein B-100/APOB Protein, Human (His, solution)
Apolipoprotein B-100/Apo B Protein, Human (His, solution) expresses in E. coli with a His tag at the N-terminus. Human Apolipoprotein B-100 (apo B-100) is the major apolipoprotein of low density lipoproteins and the principal ligand for interaction with the low density lipoprotein receptor.

Species: Human; Source: E. coli

/
HY-P72080 APOBEC3A Protein, Human (His-SUMO)
APOBEC3A protein is a DNA deaminase that limits the mobility of viruses, foreign DNA, and retrotransposons. APOBEC3A Protein, Human (His-SUMO) is the recombinant human-derived APOBEC3A protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

Species: Human; Source: E. coli

/
HY-P74625 PLTP Protein, Human (HEK293, His)
PLTP proteins are centrally involved in lipid metabolism, mediating the transfer of phospholipids and free cholesterol between lipoproteins and HDL. This includes the exchange of various molecules such as diacylglycerol, sphingomyelin, and phosphatidylcholine. PLTP Protein, Human (HEK293, His) is the recombinant human-derived PLTP protein, expressed by HEK293 , with C-10*His labeled tag.

Species: Human; Source: HEK293

/
HY-P76556 PTPMT1 Protein, Human (His)
The PTPMT1 protein is a lipid phosphatase that critically regulates cellular lipid metabolism by dephosphorylating phosphatidylglycerolphosphate (PGP) to form phosphatidylglycerol (PG). This step is critical for the biosynthesis of cardiolipin, a key mitochondrial phospholipid that regulates membrane integrity and mitochondrial activity. PTPMT1 Protein, Human (His) is the recombinant human-derived PTPMT1 protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

/
HY-P72084 Apolipoprotein E/APOE Protein, Rabbit (His-B2M, Myc)
Apolipoprotein E/APOE is essential for lipid transport between organs and is a key component of lipoproteins such as chylomicrons and high-density lipoprotein. It binds to cell receptors such as LDLR and VLDLR to promote lipoprotein uptake, and has heparin-binding activity to interact with cell surface proteoglycans. Apolipoprotein E/APOE Protein, Rabbit (His-B2M, Myc) is the recombinant Rabbit-derived Apolipoprotein E/APOE protein, expressed by E. coli , with N-10*His, C-Myc, N-B2M labeled tag.

Species: Rabbit; Source: E. coli

/
HY-P74410 Apolipoprotein H/APOH Protein, Rat (HEK293, His)
Apolipoprotein H/APOH proteins have multiple functions and can bind to negatively charged substances such as heparin and phospholipids. Its diverse interactions highlight the adaptability that is critical for preventing activation of the intrinsic coagulation cascade by binding to phospholipids on the surface of damaged cells. Apolipoprotein H/APOH Protein, Rat (HEK293, His) is the recombinant rat-derived Apolipoprotein H/APOH protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

/
HY-P75217A FABP4 Protein, Mouse (HEK293, His)

Species: Mouse; Source: HEK293

/
HY-P75504 Apolipoprotein L/APOL1 Protein, Human (sf9, His)
Apolipoprotein L (APOL1) Protein is a member of the apolipoprotein L family. Apolipoprotein L/APOL1 Protein, Human (sf9, His) is the recombinant human-derived Apolipoprotein L/APOL1 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P70160 Gastrotropin/FABP6 Protein, Human (His)
Gastrotropin/FABP6 is a fatty acid binding protein, or ileal bile acid binding protein (IBABP). FABP6 is a therapeutic target related to immune infiltration, and FABP6 inhibition inhibits cancer cell proliferation and migration. Gastrotropin/FABP6 Protein, Human (His) is the recombinant human-derived Gastrotropin/FABP6 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P700660 Apolipoprotein H/APOH Protein, Cynomolgus (HEK293, His)
Apolipoprotein H/APOH proteins have multiple functions and can bind to negatively charged substances such as heparin and phospholipids. Its diverse interactions highlight the adaptability that is critical for preventing activation of the intrinsic coagulation cascade by binding to phospholipids on the surface of damaged cells. Apolipoprotein H/APOH Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Apolipoprotein H/APOH protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

/
HY-P703419 FABP9 Protein, Human
FABP9 Protein, Human is the recombinant human-derived FABP9, expressed by E. coli , with tag Free labeled tag.

Species: Human; Source: E. coli

/
HY-P705538 APOC1 Protein, Mouse (Cell-Free, His)

Species: Mouse; Source: E. coli Cell-free

/
HY-P704001 SCP2 Protein, Human (GST)
SCP2 Protein, Human (GST) is the recombinant human-derived SCP2 protein, expressed by E. coli, with N-GST tag.

Species: Human; Source: E. coli

/
HY-P705431 METTL7B Protein, Human (His)

Species: Human; Source: E. coli

/
HY-P706289 ¹⁵N-Labeled Apolipoprotein E/APOE (His)

Species: Human; Source: E. coli

/
HY-P706291 ¹⁵N-Labeled Apolipoprotein B-48/APOB Protein, Human (His)

Species: Human; Source: E. coli

/
HY-P82793 Perilipin-1 Antibody (YA2538)
Perilipin-1 Antibody (YA2538) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Perilipin-1.

Host: Rabbit; Reactivity: Human, Mouse

/
HY-P82821 ApoB Antibody (YA2566)
ApoB Antibody (YA2566) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoB.

Host: Rabbit; Reactivity: Human

/
HY-P82297 ApoH Antibody (YA2042)
ApoH Antibody (YA2042) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoH.

Host: Rabbit; Reactivity: Human, Rat

/
HY-P82297A ApoH Antibody (YA2042)(PBS only)
ApoH Antibody (YA2042) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoH.

Host: Rabbit; Reactivity: Human, Rat

/
HY-P81888 ATP Synthase C Antibody (YA1633)
ATP Synthase C Antibody (YA1633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P81888A ATP Synthase C Antibody (YA1633)(PBS only)
ATP Synthase C Antibody (YA1633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-P82460 ATP Synthase C Antibody (YA2205)
ATP Synthase C Antibody (YA2205) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Rat

/
HY-P82460A ATP Synthase C Antibody (YA2205)(PBS only)
ATP Synthase C Antibody (YA2205) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATP Synthase C.

Host: Rabbit; Reactivity: Human, Rat

/
HY-P83236 CETP Antibody (YA2981)
CETP Antibody (YA2981) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CETP.

Host: Rabbit; Reactivity: Human

/
HY-P84902 AUP1 Antibody (YA4599)
AUP1 Antibody (YA4599) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AUP1.

Host: Mouse; Reactivity: Human, Mouse

/
HY-P84902A AUP1 Antibody (YA4599)(PBS only)
AUP1 Antibody (YA4599) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AUP1.

Host: Mouse; Reactivity: Human, Mouse

/
HY-P86295 STARD4 Antibody (YA5987)
STARD4 Antibody (YA5987) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to STARD4.

Host: Rabbit; Reactivity: Human

/
HY-P810357 CETP Antibody (YA9679)
CETP Antibody (YA9679) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to CETP.

Host: Rabbit; Reactivity: Human, Mouse, Rat

/
HY-K0358 Human CD66b+ Cell Positive Selection Kit

MCE Human CD66b+ Cell Positive Selection Kit is designed for the efficient isolation of CD66b+ cells from human peripheral blood single-cell suspensions. CD66b+ cells are first specifically labeled with the CD66b Capture Antibody and subsequently captured using Releasable Magnetic Beads. Following magnetic separation, the beads are detached from the cell surface using Magnetic Beads Release Buffer, resulting in highly purified CD66b+ cells free of residual magnetic bead labeling.

/
HY-K0360 Mouse CD4+ CD25+ Regulatory T Cell Positive Selection Kit

MCE Mouse CD4+ CD25+ Regulatory T Cell Positive Selection Kit is designed for the isolation of CD4+ CD25+ regulatory T cells (Tregs) from mouse splenic single-cell suspensions. The kit utilizes a two-step isolation strategy. First, CD4 Enrichment Beads are used to deplete non-target cells and enrich CD4+ T cells. Subsequently, CD25 Capture Antibody specifically binds to CD25+ cells, which are then captured by Releasable Magnetic Beads. Following isolation, the magnetic beads are gently detached from the cell surface using Magnetic Beads Release Buffer, yielding label-free CD4+ CD25+ regulatory T cells with no residual magnetic beads.

/
HY-K0613 Oil Red O Staining Kit for Cultured Cells

MCE Oil Red O Staining Kit for Cultured Cells consists of Oil Red O staining solution and hematoxylin. It is used to demonstrate fat degeneration and abnormal lipid deposition in cultured cells, particularly when multiple neutral fat droplets are present within the cells. This kit helps in identifying lipid changes and their nature in cultured cells. It is important to note that samples should not be fixed with ethanol-containing fixatives, as ethanol may interfere with lipid staining. The positive staining result for fat typically appears orange-yellow to red, with the exact color depending on the lipid concentration.

/
HY-K0614 Oil Red O Staining Kit for Cell Smears

MCE Oil Red O Staining Kit for Cell Smears effectively stains lipid droplets of various sizes, including smaller lipid droplets, and preferentially adsorbs dye from the solvent. It is suitable for staining oil red O in cell smears, bone marrow smears, fluid smears, blood smears, and other samples. When using the kit, specimens should not be fixed with fixatives containing ethanol. If fixation is required, 10% formalin can be used. The positive staining result for fat typically appears orange-yellow to red, with the exact color varying depending on the lipid concentration.

/
HY-K1066 Exosome Purification Filter

MCE Exosome Purification Filter is designed for use with the corresponding exosome extraction/purification kit and is suitable for the further purification of crude exosome preparations. It helps remove residual impurities and facilitates the preparation of exosome samples with improved purity.

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

/
HY-K3019 Lipid Concentrate (Chemically Defined)

MCE Lipid Concentrate (Chemically Defined) is a concentrated lipid solution with a clearly defined chemical composition, which can be added to cell culture media as an additive for serum-free or low-serum cell culture systems.

/

Keywords

atherogenic lipoproteins | apolipoprotein B | LDL cholesterol | lipoprotein(a) | residual lipid risk | non-HDL cholesterol | atherosclerosis | RNA therapeutics